Patients: What They Really Want to Know about Their Disease

When we decide that 30-day mortality to repair an abdominal aortic aneurysm (AAA) is at least twice as high with conventional surgery compared against endovascular treatment, many of us think choosing a strategy is far from hard, and recent stats show exactly that. However, are we sure our patient agrees with us, or at least understands what our choice involves?

Oportunidades perdidas en pacientes con enfermedad vascular periférica

Helping patients make such vital decisions may vary depending on the clinical situation. As regards AAA (though this could be applied to any other condition, even when we decide against a procedure) this can be especially complex.

Patients must be clearly informed about absolute risks (rather than relative).

This study looks at the way complications are informed, especially mortality, compared against the information provided to patients on these same events when AAA repair is elective.


Read also: ESC 2018 | ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty


Of 47 contemporary randomized and observational studies or registries, only two presented differences in mortality risk in absolute terms.

This without taking into account the lack of common definitions, because mortality will be mortality, but the softest points should be analyzed according to each study definition, which have been always different.

We should improve adhesion to the systematic reporting of events, standardized, absolute risk differences especially, to facilitate communicating evidence to patients for them to be able to make informed decisions.


Read also: Would TAVR Have a Similar Benefit in Patients with Low Flow, Low Gradient, and Preserved Ejection Fraction?


Our patients and their families might have a different opinion of what is important, different from what we usually consider important (e.g.: 30-day mortality or vascular complications).

For them the chance to remain independent, to be free of pain or disability, to avoid amputation or to quickly return home might be more important than survival per se.

This disagreement is part of the agenda of the next European Society of Cardiovascular Surgeons Guidelines to be presented in 2019. For the first time, patient perspective will be taken into account, and it is being elaborated on together with patients and their representatives.


Read also: EXCEL Outcomes: PCI vs CABG in Patients with Prior Cerebrovascular disease


Also defining and standardizing a minimum of key events with the same criterion to report all studies on AAA treatment to come.

This will let us provide the adequate and necessary information for our patients, and their families, to decide the best course of action.

The question “what does the patient want to know” has no answer. Each patient might want different things at different times in the course of their treatment, and even has the right not to know.

Realizing what patients are prepared to know about their condition and the risks involved is an art we should practice, one that should have the highest priority, bearing in mind we do not treat diseases but rather persons.

Original Title: What Does the Patient Really Want to Know?

Reference: Anders Wanhainen. Eur J Vasc Endovasc Surg, article in press.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....